Jihad Slim, MD
Infectious Disease · Newark, NJNPI 1366411076
Payments from drug & device makers
Across 2,826 payments — averaging $2355.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3.4M
- Gilead$1M
- Janssen Research & Development, LLC$754K
- Merck$486K
- Theratechnologies Inc.$357K
- AbbVie$256K
- plus $393K from 20 others
Across 28 payments — averaging $189.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$4K
- Viiv Healthcare Company$1K
What the payments were for
- Consulting fees$289,82514%
- Speaking & faculty fees$1,564,11674%
- Travel & lodging$192,3769%
- Food & beverage$61,5863%
- Education$6400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 985 | $3,371,117 |
| Gilead | 772 | $1,038,669 |
| Janssen Research & Development, LLC | 54 | $753,794 |
| Merck | 360 | $486,012 |
| Theratechnologies Inc. | 194 | $356,888 |
| AbbVie(2 entities) | 213 | $255,649 |
| GSK | 33 | $180,794 |
| EMD Serono, Inc. | 63 | $64,648 |
| Janssen Products, LP | 60 | $62,109 |
| Hoffmann-la Roche Limited | 5 | $26,567 |
| Vertex | 1 | $23,601 |
| Janssen Scientific Affairs, LLC | 32 | $13,947 |
| Tetraphase Pharmaceuticals, Inc. | 14 | $6,435 |
| Genentech, Inc. | 2 | $4,329 |
| Modernatx, Inc. | 5 | $3,666 |
| Napo Pharmaceuticals Inc | 13 | $2,940 |
| Biotest AG | 1 | $2,500 |
| Shionogi Inc | 1 | $800 |
| Genentech USA, Inc. | 1 | $362 |
| Johnson & Johnson | 10 | $308 |
| Comsort, Inc | 1 | $100 |
| Astellas Pharma US Inc | 1 | $99 |
| Cumberland Pharmaceuticals, Inc. | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Madrigal Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,655,407 in reported general payments places this provider in the 95th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 708 | $2,780,378 |
| DovatoDolutegravir Sodium/Lamivudine | 798 | $2,290,714 |
| EpclusaSofosbuvir/Velpatasvir | 63 | $1,445,825 |
| TivicayDolutegravir Sodium | 438 | $1,018,380 |
| PifeltroDoravirine | 437 | $745,335 |
| RukobiaFostemsavir Tromethamine | 72 | $638,212 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 121 | $572,513 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 113 | $415,659 |
| JulucaDolutegravir/Rilpivirine | 78 | $260,191 |
| Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir | 29 | $229,355 |
| CabenuvaCabotegravir/Rilpivirine | 30 | $194,471 |
| TrogarzoIbalizumab-Uiyk | 13 | $163,033 |
| PrezcobixDarunavir/Cobicistat | 62 | $148,415 |
| DescovyEmtricitabine/Tenofov Alafenam | 54 | $120,299 |
| Egrifta SvTesamorelin Acetate | 12 | $84,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay, Rukobia, Juluca, Cabenuva | $3,371,117 | $4,401,9671,416 claims |
| GileadBiktarvy, Epclusa, Descovy, Vemlidy | $1,038,669 | $4,374,068845 claims |
| MerckPifeltro, Isentress, Delstrigo | $486,012 | $837,752477 claims |
| Janssen Products, LPSymtuza | $62,109 | $572,513121 claims |
| Theratechnologies Inc.Trogarzo, Egrifta Sv | $356,888 | $247,59025 claims |
| Johnson & JohnsonPrezcobix | $308 | $148,41562 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Newark
- Shobha SwaminathanNewark$1.4M
- David AllandNewark$485K
- Maria SzabelaNewark$474K
- Sally HodderNewark$168K
- Debra ChewNewark$105K
- Tilly VarugheseNewark$98K
- Madhu SuryadevaraNewark$24K
- Lisa DeverNewark$18K
- Wanda FigueroaNewark$14K
- Jerrold EllnerNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.